Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3291 |
| PDBID: | 6Z1V |
| Chains: | B_A |
| Organism: | Homo sapiens, Lama glama |
| Method: | XRD |
| Resolution (Å): | 1.33 |
| Reference: | 10.26508/lsa.202000883 |
| Antibody | |
| Antibody: | 4E8 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | EC2 domain of CD9 |
| Antigen mutation: | No |
| Durg Target: | P21926 |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >6Z1V_B|Chain B|Nanobody 4E8|Lama glama (9844) EVQLVESGGRLVRTGGSLRLSCAASGRTFSNYVMGWFRQAPGKEREVVAAITWSGDITWHADFVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAATERWGLRAPADWGSWGQGTQVTVSSHGSGLVPRGSGGGHHHHHH |
Antigen
Chain: A
Mutation: NULL
| >6Z1V_A|Chain A|CD9 antigen|Homo sapiens (9606) GSKDEVIKEVQEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVEQFISDICPKKDVLETFTVKSCPDAIKEVFDNAAAHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: SER30 ASN31 VAL33 VAL47 ALA50 THR52 TRP53 SER54 ASP56 ILE57 THR58 TRP59 GLU100 ARG101 TRP102 GLY103 LEU104 ARG105 TRP110 A: TYR129 LEU155 GLY157 GLY158 VAL159 GLU160 GLN161 SER164 LYS169 LEU173 GLU174 THR175 PHE176 THR177 VAL178 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
